Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
- 18 January 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 21 (1), 2
- https://doi.org/10.1007/s11912-019-0750-1
Abstract
This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.Keywords
This publication has 106 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic MelanomaClinical Cancer Research, 2012
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T CellsThe Journal of Immunology, 2010
- Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage CommitmentImmunity, 2009
- Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptorNature, 2008
- A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturationBlood, 2005
- Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-DioxygenaseScience, 2002